The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The warm sunshine of spring is a welcome change from the cold and brutal winds of winter in the Upper Midwest. However, with ...

today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

New clinical insights support U.S. doctors in using transoral robotic surgery (TORS) to personalize treatment plans for ...

Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase I ...

A South Carolina native and two-time Super Bowl champion celebrated a life win recently. Jim Stuckey is cancer-free after an ...